AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9439560 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced healthy-living advice
Number of subjects: 227
Study 9439560 — intervention group
Group type: COMPARATOR
Intervention: Basic healthy-living advice
Number of subjects: 227
Study 7931477 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 10 mg twice daily by mouth for 1 year
Number of subjects: 966
Study 7931477 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide 60 mg/m2/d by mouth for 1 year, methotrexate 15 mg/m2 IV weekly for 1 year, fluorouracil (5‐FU) 400 mg/m2 IV weekly for 1 year, vincristine .625 mg/m2 IV weekly for the first 10 weeks, and prednisone during weeks 1 to 10 with doses decreasing from 30 mg/m2 to 2.5 mg/m2 (CMFVP)
Number of subjects: 966
Study 7931477 — intervention group
Group type: COMPARATOR
Intervention: Combination of tamoxifen and CMFVP
Number of subjects: 966
Study 2834996 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-MU recombinant alfa-2b interferon
Number of subjects: 220
Study 2834996 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-MU recombinant alfa-2b interferon
Number of subjects: 220
Study 2834996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 30158512 — intervention group
Group type: EXPERIMENTAL
Intervention: Video + retelling group
Number of subjects: 0
Study 30158512 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 26990920 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDT) with the Symplicity™ catheter
Number of subjects: 25
Study 26990920 — intervention group
Group type: COMPARATOR
Intervention: Continuing medical therapy
Number of subjects: 25
Study 25672380 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (25 mg/g lidocaine and 25 mg/g prilocaine)
Number of subjects: 32
Study 25672380 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable 2% lidocaine
Number of subjects: 32
Study 25672380 — intervention group
Group type: COMPARATOR
Intervention: Topical 2% benzocaine
Number of subjects: 32
Study 25672380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23995608 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban (bolus of 0.080 mg/kg followed by an infusion of 0.140 mg/kg per hour)
Number of subjects: 13229
Study 23995608 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin plus eptifibatide
Number of subjects: 13229
Study 23995608 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban
Number of subjects: 13229
Study 21106390 — intervention group
Group type: EXPERIMENTAL
Intervention: 350-500 μm particles
Number of subjects: 160
Study 21106390 — intervention group
Group type: COMPARATOR
Intervention: 500-700 μm particles
Number of subjects: 160
Study 19203476 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 40
Study 19203476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 40
Study 19203476 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 16608147 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of intoxication of the crowd during the visit
Number of subjects: 1025
Study 16608147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean level of intoxication at the bar level
Number of subjects: 1025
Study 16608147 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of intoxication at the person level
Number of subjects: 1025
Study 16608147 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-incident level interaction between intoxication and severity of aggression
Number of subjects: 1025
Study 13680569 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle endurance program (exercise 3 times a week for 12 weeks at a set wattage)
Number of subjects: 26
Study 11231385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam and intravenous meperidine
Number of subjects: 107
Study 11231385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 9513074 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from five-membered-ring agents (cimetidine, ranitidine, famotidine) to roxatidine in the treatment of five-membered-ring resistant ulcers.
Number of subjects: 34
Study 9513074 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from roxatidine to five-membered-ring agents in the treatment of roxatidine-resistant ulcers.
Number of subjects: 34
Study 8296753 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 88
Study 8296753 — intervention group
Group type: COMPARATOR
Intervention: Conventional antiarrhythmic drugs
Number of subjects: 88
Study 2498141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide (400 mg, three times daily)
Number of subjects: 20
Study 2498141 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg, once daily)
Number of subjects: 20
Study 2498141 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Atenolol and Tocainide
Number of subjects: 20
Study 4929685 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg phenazocine hydrobromide (Narphen)
Number of subjects: 0
Study 4929685 — intervention group
Group type: COMPARATOR
Intervention: 10 mg morphine sulphate
Number of subjects: 0
Study 29220855 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC therapy (dabigatran 150 mg BID, apixaban 5 mg BID, dabigatran 110 mg BID, rivaroxaban 20 mg OD, rivaroxaban 15 mg OD, apixaban 2.5 mg OD)
Number of subjects: 76
Study 28059799 — intervention group
Group type: EXPERIMENTAL
Intervention: B&L Group therapy (Ben‐Yishay & Lakin model)
Number of subjects: 9
Study 28059799 — intervention group
Group type: EXPERIMENTAL
Intervention: S&M Group therapy (Sohlberg & Mateer model)
Number of subjects: 9
Study 26678641 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 1 mg/d for 2 weeks
Number of subjects: 149
Study 26678641 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet for 2 weeks)
Number of subjects: 149
Study 26678641 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 149
Study 22083142 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE exercise intervention
Number of subjects: 0
Study 22083142 — intervention group
Group type: COMPARATOR
Intervention: Health-and-wellness contact control
Number of subjects: 0
Study 21516477 — intervention group
Group type: EXPERIMENTAL
Intervention: Short latency afferent inhibition (SAI) of motor cortex in MB-positive group (n=13)
Number of subjects: 28
Study 21516477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE) total score and subscores in MB-positive group (n=13)
Number of subjects: 28
Study 21516477 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of SAI with MMSE score in MB-positive group (n=13)
Number of subjects: 28
Study 21516477 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SAI in MB-positive group (n=13) with MB-negative group (n=15) and healthy subjects (n=20)
Number of subjects: 28
Study 18312153 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg b.i.d. (n = 17)
Number of subjects: 34
Study 18312153 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg b.i.d. (n = 17)
Number of subjects: 34
Study 18312153 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 400 mg
Number of subjects: 34
Study 18312153 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 150 mg
Number of subjects: 34
Study 18312153 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 34
Study 16531897 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHO
Number of subjects: 14
Study 16531897 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% CHO
Number of subjects: 14
Study 16531897 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 14
Study 12672180 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 treatment
Number of subjects: 6
Study 12672180 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro IL-10 treatment
Number of subjects: 6
Study 10989856 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (30 ng/mL) co-administered with ketamine
Number of subjects: 11
Study 10989856 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (50, 100, or 150 ng/mL)
Number of subjects: 11
Study 10989856 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of Midazolam and Ketamine
Number of subjects: 11
Study 10989856 — intervention group
Group type: COMPARATOR
Intervention: Ketamine and Midazolam
Number of subjects: 11
Study 9183229 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens, 0.625 mg/d
Number of subjects: 76
Study 9183229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin sodium, 20 mg/d
Number of subjects: 76
Study 9183229 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens plus pravastatin
Number of subjects: 76
Study 9183229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 1316405 — intervention group
Group type: EXPERIMENTAL
Intervention: Single clinic measurement of DBP
Number of subjects: 100
Study 1316405 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime ambulatory recording of DBP
Number of subjects: 100
Study 1316405 — intervention group
Group type: EXPERIMENTAL
Intervention: Average ambulatory DBP
Number of subjects: 100
Study 1316405 — intervention group
Group type: EXPERIMENTAL
Intervention: Single clinic DBP readings
Number of subjects: 100
Study 30753321 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group 1 consumed beer up to a breath alcohol concentration (BrAC) ≥0.05% and then wine to BrAC ≥0.11%.
Number of subjects: 90
Study 30753321 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group 2 consumed wine to BrAC ≥0.11% and then beer to BrAC ≥0.05%.
Number of subjects: 90
Study 30753321 — intervention group
Group type: COMPARATOR
Intervention: Control group subjects consumed either only beer or only wine.
Number of subjects: 90
Study 30753321 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (study groups and control) were assessed for hangover severity using the Acute Hangover Scale rating.
Number of subjects: 90
Study 29243849 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic patient education
Number of subjects: 580
Study 29243849 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 580
Study 27530087 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week structured exercise program (aerobic and resistance training)
Number of subjects: 86
Study 24548114 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin before and after exercise (AA)
Number of subjects: 102
Study 24548114 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin before and placebo after exercise (AP)
Number of subjects: 102
Study 24548114 — intervention group
Group type: COMPARATOR
Intervention: Placebo before and aspirin after exercise (PA)
Number of subjects: 102
Study 24548114 — intervention group
Group type: COMPARATOR
Intervention: Placebo before and after exercise (PP)
Number of subjects: 102
Study 21224242 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask use and hand hygiene compliance
Number of subjects: 0
Study 21224242 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 0
Study 20191779 — intervention group
Group type: COMPARATOR
Intervention: 0 microg x kg(‐1) (placebo)
Number of subjects: 75
Study 20191779 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg x kg(‐1)
Number of subjects: 75
Study 20191779 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microg x kg(‐1)
Number of subjects: 75
Study 20191779 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 microg x kg(‐1)
Number of subjects: 75
Study 20191779 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 microg x kg(‐1)
Number of subjects: 75
Study 17914519 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg.kg(‐1)
Number of subjects: 40
Study 17914519 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.1 mg.kg(‐1)
Number of subjects: 40
Study 16195988 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treadmill run of 60 min at 75 % VO2max
Number of subjects: 0
Study 16195988 — intervention group
Group type: EXPERIMENTAL
Intervention: Long treadmill run of 120 min at 60 % VO2max
Number of subjects: 0
Study 16195988 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive interval training program (10 x 1000 m, ca. 35 min, VO2max 88 %)
Number of subjects: 0
Study 16195988 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive marathon run (MA) within 260 +/- 39 min at VO2max ca. 65 %
Number of subjects: 0
Study 16195988 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive exercise (ET) at 80 % VO2max for 23.7 +/- 7 min
Number of subjects: 0
Study 16195988 — intervention group
Group type: COMPARATOR
Intervention: Moderate exercise (MT) at 60 % VO2max for 23.7 +/- 7 min
Number of subjects: 0
Study 12100298 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (140 microg once daily)
Number of subjects: 280
Study 12100298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (200 microg once daily)
Number of subjects: 280
Study 12100298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 10430530 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf muscle function assessment in patients with chronic venous disease
Number of subjects: 49
Study 10430530 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (age- and sex-matched)
Number of subjects: 49
Study 10430530 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak torque/body weight (strength)
Number of subjects: 49
Study 10430530 — intervention group
Group type: EXPERIMENTAL
Intervention: Total work (endurance)
Number of subjects: 49
Study 7675822 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (0.025 microgram/kg/min)
Number of subjects: 0
Study 7675822 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (3.0 micrograms/kg/min)
Number of subjects: 0
Study 7675822 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 2382243 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (40 mg in 4 ml buffered saline)
Number of subjects: 10
Study 2382243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 ml of diluent solution)
Number of subjects: 10
Study 6782480 — intervention group
Group type: COMPARATOR
Intervention: verapamil
Number of subjects: 16
Study 30654798 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise (CE) at 70% WRmax for 30 minutes
Number of subjects: 16
Study 30654798 — intervention group
Group type: COMPARATOR
Intervention: Intermittent exercise (IE) at 70% WRmax for 60 minutes (1-min work: 1-min rest)
Number of subjects: 16
Study 28382061 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing technique of blowing
Number of subjects: 166
Study 28382061 — intervention group
Group type: COMPARATOR
Intervention: Valsalva maneuver
Number of subjects: 166
Study 26378030 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ injury prevention program
Number of subjects: 61
Study 26378030 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 61
Study 26378030 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ program vs Control
Number of subjects: 61
Study 24010954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment (scaling and root planing)
Number of subjects: 100
Study 24010954 — intervention group
Group type: COMPARATOR
Intervention: Community periodontal treatment (one session of supragingival plaque removal)
Number of subjects: 100
Study 21106918 — intervention group
Group type: EXPERIMENTAL
Intervention: French National Nutrition and Health Program Guideline Score (PNNS-GS) adherence
Number of subjects: 2135
Study 19512881 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-S (Laryngeal Mask Supreme)
Number of subjects: 60
Study 19512881 — intervention group
Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 60
Study 17341712 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg of oral conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate)
Number of subjects: 14749
Study 17341712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14749
Study 17341712 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal ECG at baseline
Number of subjects: 14749
Study 17341712 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor baseline ECG abnormalities
Number of subjects: 14749
Study 17341712 — intervention group
Group type: EXPERIMENTAL
Intervention: Major baseline ECG abnormalities
Number of subjects: 14749
Study 17341712 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident ECG abnormalities
Number of subjects: 14749
Study 15541358 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor
Number of subjects: 30
Study 15541358 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched metastasis
Number of subjects: 30
Study 15541358 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic specimens
Number of subjects: 30
Study 11677862 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic drugs (Homéogène 46 and Sédatif PC)
Number of subjects: 61
Study 11677862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9366318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical capsaicin (1 to 2 mmol/l. in 30% ethanol in saline)
Number of subjects: 79
Study 9366318 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (30% ethanol in saline)
Number of subjects: 79
Study 7702808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 25
Study 7702808 — intervention group
Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 25
Study 2892658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 20
Study 2892658 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg daily)
Number of subjects: 20
Study 31821623 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 Hz/1.1 Hz/1.6 Hz electrical stimulation (square wave, pulse width:1 ms) at bladder dome (BD), trigone, proximal, membranous (only males), or distal urethra
Number of subjects: 90
Study 31308360 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release nutrient (DRN)
Number of subjects: 19
Study 31308360 — intervention group
Group type: COMPARATOR
Intervention: Unformulated nutrients (UN)
Number of subjects: 19
Study 28558734 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotoner gloves (intervention)
Number of subjects: 0
Study 28558734 — intervention group
Group type: COMPARATOR
Intervention: Placebo gloves (control)
Number of subjects: 0
Study 25062613 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity prevention intervention
Number of subjects: 28
Study 24043745 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/d
Number of subjects: 656
Study 24043745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (BSC)
Number of subjects: 656
Study 21281871 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast with enhanced presentation mode
Number of subjects: 99
Study 21281871 — intervention group
Group type: COMPARATOR
Intervention: Neutral presentation mode
Number of subjects: 99
Study 20225464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mylar matrix with nanofiller
Number of subjects: 4
Study 20225464 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhybrid resin
Number of subjects: 4
Study 20225464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid resin
Number of subjects: 4
Study 20225464 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfilled resin with aluminum oxide discs
Number of subjects: 4
Study 20225464 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond paste
Number of subjects: 4
Study 20225464 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum oxide discs
Number of subjects: 4
Study 20225464 — intervention group
Group type: COMPARATOR
Intervention: Control (intact human enamel)
Number of subjects: 4
Study 17036388 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol electrolyte solution on the same day as colonoscopy
Number of subjects: 177
Study 17036388 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate on the same day as colonoscopy
Number of subjects: 177
Study 17036388 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol electrolyte solution on the day prior to colonoscopy
Number of subjects: 177
Study 17036388 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate on the day prior to colonoscopy
Number of subjects: 177
Study 17036388 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation on the same day as colonoscopy
Number of subjects: 177
Study 17036388 — intervention group
Group type: COMPARATOR
Intervention: Preparation on the day prior to colonoscopy
Number of subjects: 177
Study 15231912 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins with iron (10 mg/day) for 3 months
Number of subjects: 284
Study 15231912 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard-dose multivitamins without iron)
Number of subjects: 284
Study 15231912 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (regardless of assignment)
Number of subjects: 284
Study 15231912 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants whose mothers were anemic during pregnancy
Number of subjects: 284
Study 11231988 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 8
Study 11231988 — intervention group
Group type: COMPARATOR
Intervention: No lipid infusion (control)
Number of subjects: 8
Study 9429451 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 1/2-hour nap period four times a day, beds covered and left undisturbed
Number of subjects: 22
Study 9429451 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 22
Study 8284290 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic Villus Sampling (CVS)
Number of subjects: 4003
Study 8284290 — intervention group
Group type: COMPARATOR
Intervention: Amniocentesis (AC)
Number of subjects: 4003
Study 8284290 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical (TC) CVS
Number of subjects: 4003
Study 8284290 — intervention group
Group type: COMPARATOR
Intervention: Transabdominal (TA) CVS
Number of subjects: 4003